English

Conatus Pharmaceuticals Inc

EDGAR

CNAT Quarterly report (10-Q) · filed 2023-11-09

79 filing records in this dataset, filed from 2013-06-14 to 2023-11-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

5 thousand USD

2023 Q3 · USD

Exact inputs and evidence

Revenue: 5000 USD Source

Operating margin

-70,500%

2023 Q3 · %

Exact inputs and evidence

Operating Income: -3525000 USD Source
Revenue: 5000 USD Source

Operating cash flow

-2.69 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -7635000 USD Source
Operating Cash Flow: -4946000 USD Source

Cash and cash equivalents: 4.6 million USD 2023-09-30 Source
Exact value

4600000 USD
Long-term debt including current maturities: 310 thousand USD 2021-03-31 Source
Exact value

310000 USD
Shares outstanding: 4.27 million shares 2023-09-30 Source
Exact value

4271759 shares

Reported share-count change

0.00% · 0 shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

4271759 shares · 2022-09-30· Source
4271759 shares · 2023-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

19 thousand USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Revenue: 3769000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 3765000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 5000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 5000 USD · 2023-04-01 – 2023-06-30 Source
Revenue: 5000 USD · 2023-07-01 – 2023-09-30 Source

Net income

-10.1 million USD

2019-04-01 – 2020-03-31

Exact inputs and evidence

Net income: -656000 USD · 2019-04-01 – 2019-06-30 Source
Net income: -3253000 USD · 2019-07-01 – 2019-09-30 Source
Net income: -2729000 USD · 2019-10-01 – 2019-12-31 Source
Net income: -3481000 USD · 2020-01-01 – 2020-03-31 Source

Operating cash flow

-10.1 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Operating cash flow: -9683000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -7244000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -2550000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -4946000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -2550000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -7635000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -4946000 USD · 2023-01-01 – 2023-06-30 Source

Capital expenditure

216 thousand USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Capital expenditure: 15000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 206000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 15000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 215000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 206000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 216000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 215000 USD · 2022-01-01 – 2022-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-11-09.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2022-12-31
Operating income: 9 of 11 periods available· newest 2022-12-31
Net income: 8 of 11 periods available· newest 2019-12-31
Operating cash flow: 11 of 11 periods available· newest 2022-12-31
Capital expenditure: 11 of 11 periods available· newest 2022-12-31
Total assets: 8 of 11 periods available· newest 2022-12-31
Total liabilities: 4 of 11 periods available· newest 2022-12-31
Current assets: 8 of 11 periods available· newest 2022-12-31
Current liabilities: 8 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2020-12-31
Shares outstanding: 8 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+265.2%

Prior period

USD 1.03 million

2021-01-01 – 2021-12-31
Current period

USD 3.77 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

3769000 − 1032000 = 2737000 USD

1032000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
3769000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Conatus Pharmaceuticals Inc · 2022-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Year-over-year change in Revenue: 2737000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 3769000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1506834 Filing: 000095017023007056 Input fundies:Revenue: 1032000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1508900 Filing: 000095017023007056
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 4.85 million

Prior period

−USD 14.53 million

2021-01-01 – 2021-12-31
Current period

−USD 9.68 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-9683000 − -14532000 = 4849000 USD

-14532000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-9683000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Conatus Pharmaceuticals Inc · 2022-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Year-over-year change in Operating cash flow: 4849000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -9683000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1934664 Filing: 000095017023007056 Input fundies:OperatingCashFlow: -14532000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1936986 Filing: 000095017023007056
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-10.4%

Prior period

USD 241,000

2021-01-01 – 2021-12-31
Current period

USD 216,000

2022-01-01 – 2022-12-31

Exact inputs and evidence

216000 − 241000 = -25000 USD

241000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
216000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Conatus Pharmaceuticals Inc · 2022-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Year-over-year change in Capital expenditure: -25000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 216000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1942799 Filing: 000095017023007056 Input fundies:CapitalExpenditure: 241000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1945110 Filing: 000095017023007056
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 3.77 million 100% of revenue
Operating costs Derived USD 14.41 million 382% of revenue
Operating income −USD 10.64 million −282% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −USD 9.68 million −257% of revenue
Capital expenditure USD 216,000 5.7% of revenue
Free cash flow Derived −USD 9.9 million −263% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Not shown: operating income or net income is not reported.
2016 Operating loss: operating costs were 3,834% of revenue.
2017 Operating loss: operating costs were 150% of revenue.
2018 Operating loss: operating costs were 154% of revenue.
2019 Operating loss: operating costs were 129% of revenue.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2015-01-01 – 2015-12-31	0	24130702 Derived	-24130702	17924 Derived	-24148626	-22634709 Derived	Source 2015-01-01 – 2015-12-31: 0 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -24130702 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -24148626 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -22546185 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 88524 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	799000	30631000 Derived	-29832000	-98000 Derived	-29734000	26887000 Derived	Source 2016-01-01 – 2016-12-31: 799000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -29832000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -29734000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 26997000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 110000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	35377000	52927000 Derived	-17550000	-154000 Derived	-17396000	-33234000 Derived	Source 2017-01-01 – 2017-12-31: 35377000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -17550000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -17396000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -33209000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 25000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	33586000	51863000 Derived	-18277000	-267000 Derived	-18010000	-34923000 Derived	Source 2018-01-01 – 2018-12-31: 33586000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -18277000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -18010000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -34857000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 66000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	11454000	14773000 Derived	-3319000	8066000 Derived	-11385000	-1443000 Derived	Source 2019-01-01 – 2019-12-31: 11454000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -3319000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -11385000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -1291000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 152000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	2059000	20917000 Derived	-18858000	Unavailable	Unavailable	-12103000 Derived	Source 2020-01-01 – 2020-12-31: 2059000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -18858000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -12054000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 49000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1032000	16489000 Derived	-15457000	Unavailable	Unavailable	-14773000 Derived	Source 2021-01-01 – 2021-12-31: 1032000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -15457000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -14532000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 241000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	3769000	14412000 Derived	-10643000	Unavailable	Unavailable	-9899000 Derived	Source 2022-01-01 – 2022-12-31: 3769000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -10643000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -9683000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 216000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 3.8M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	0	Revenue: 0 Open source
20162016-12-31	Revenue	799000	Revenue: 799000 Open source
20172017-12-31	Revenue	35377000	Revenue: 35377000 Open source
20182018-12-31	Revenue	33586000	Revenue: 33586000 Open source
20192019-12-31	Revenue	11454000	Revenue: 11454000 Open source
20202020-12-31	Revenue	2059000	Revenue: 2059000 Open source
20212021-12-31	Revenue	1032000	Revenue: 1032000 Open source
20222022-12-31	Revenue	3769000	Revenue: 3769000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

265.2% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20162016-12-31	Year over year	No prior comparable period	Revenue: 799000 Open source Revenue: 0 Open source
20172017-12-31	Year over year	4,327.7%	Revenue: 35377000 Open source Revenue: 799000 Open source
20182018-12-31	Year over year	-5.1%	Revenue: 33586000 Open source Revenue: 35377000 Open source
20192019-12-31	Year over year	-65.9%	Revenue: 11454000 Open source Revenue: 33586000 Open source
20202020-12-31	Year over year	-82%	Revenue: 2059000 Open source Revenue: 11454000 Open source
20212021-12-31	Year over year	-49.9%	Revenue: 1032000 Open source Revenue: 2059000 Open source
20222022-12-31	Year over year	265.2%	Revenue: 3769000 Open source Revenue: 1032000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -282.4% 2022

Net margin -99.4% 2019

Free cash flow margin -262.6% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	Not reported	Operating Income: -24130702 Open source Revenue: 0 Open source
20162016-12-31	Operating margin	-3,733.7%	Operating Income: -29832000 Open source Revenue: 799000 Open source
20172017-12-31	Operating margin	-49.6%	Operating Income: -17550000 Open source Revenue: 35377000 Open source
20182018-12-31	Operating margin	-54.4%	Operating Income: -18277000 Open source Revenue: 33586000 Open source
20192019-12-31	Operating margin	-29%	Operating Income: -3319000 Open source Revenue: 11454000 Open source
20202020-12-31	Operating margin	-915.9%	Operating Income: -18858000 Open source Revenue: 2059000 Open source
20212021-12-31	Operating margin	-1,497.8%	Operating Income: -15457000 Open source Revenue: 1032000 Open source
20222022-12-31	Operating margin	-282.4%	Operating Income: -10643000 Open source Revenue: 3769000 Open source
20152015-12-31	Net margin	Not reported	Net Income: -24148626 Open source Revenue: 0 Open source
20162016-12-31	Net margin	-3,721.4%	Net Income: -29734000 Open source Revenue: 799000 Open source
20172017-12-31	Net margin	-49.2%	Net Income: -17396000 Open source Revenue: 35377000 Open source
20182018-12-31	Net margin	-53.6%	Net Income: -18010000 Open source Revenue: 33586000 Open source
20192019-12-31	Net margin	-99.4%	Net Income: -11385000 Open source Revenue: 11454000 Open source
2020-12-31	Net margin	Not reported	Revenue: 2059000 Open source
2021-12-31	Net margin	Not reported	Revenue: 1032000 Open source
2022-12-31	Net margin	Not reported	Revenue: 3769000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -22546185 Open source Capital Expenditure: 88524 Open source
20162016-12-31	Free cash flow margin	3,365.1%	Revenue: 799000 Open source Operating Cash Flow: 26997000 Open source Capital Expenditure: 110000 Open source
20172017-12-31	Free cash flow margin	-93.9%	Revenue: 35377000 Open source Operating Cash Flow: -33209000 Open source Capital Expenditure: 25000 Open source
20182018-12-31	Free cash flow margin	-104%	Revenue: 33586000 Open source Operating Cash Flow: -34857000 Open source Capital Expenditure: 66000 Open source
20192019-12-31	Free cash flow margin	-12.6%	Revenue: 11454000 Open source Operating Cash Flow: -1291000 Open source Capital Expenditure: 152000 Open source
20202020-12-31	Free cash flow margin	-587.8%	Revenue: 2059000 Open source Operating Cash Flow: -12054000 Open source Capital Expenditure: 49000 Open source
20212021-12-31	Free cash flow margin	-1,431.5%	Revenue: 1032000 Open source Operating Cash Flow: -14532000 Open source Capital Expenditure: 241000 Open source
20222022-12-31	Free cash flow margin	-262.6%	Revenue: 3769000 Open source Operating Cash Flow: -9683000 Open source Capital Expenditure: 216000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -9.7M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	-22546185	Operating Cash Flow: -22546185 Open source
20162016-12-31	Operating cash flow	26997000	Operating Cash Flow: 26997000 Open source
20172017-12-31	Operating cash flow	-33209000	Operating Cash Flow: -33209000 Open source
20182018-12-31	Operating cash flow	-34857000	Operating Cash Flow: -34857000 Open source
20192019-12-31	Operating cash flow	-1291000	Operating Cash Flow: -1291000 Open source
20202020-12-31	Operating cash flow	-12054000	Operating Cash Flow: -12054000 Open source
20212021-12-31	Operating cash flow	-14532000	Operating Cash Flow: -14532000 Open source
20222022-12-31	Operating cash flow	-9683000	Operating Cash Flow: -9683000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -9.9M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	-22634709	Operating Cash Flow: -22546185 Open source Capital Expenditure: 88524 Open source
20162016-12-31	Free cash flow	26887000	Operating Cash Flow: 26997000 Open source Capital Expenditure: 110000 Open source
20172017-12-31	Free cash flow	-33234000	Operating Cash Flow: -33209000 Open source Capital Expenditure: 25000 Open source
20182018-12-31	Free cash flow	-34923000	Operating Cash Flow: -34857000 Open source Capital Expenditure: 66000 Open source
20192019-12-31	Free cash flow	-1443000	Operating Cash Flow: -1291000 Open source Capital Expenditure: 152000 Open source
20202020-12-31	Free cash flow	-12103000	Operating Cash Flow: -12054000 Open source Capital Expenditure: 49000 Open source
20212021-12-31	Free cash flow	-14773000	Operating Cash Flow: -14532000 Open source Capital Expenditure: 241000 Open source
20222022-12-31	Free cash flow	-9899000	Operating Cash Flow: -9683000 Open source Capital Expenditure: 216000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

29.9% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2015-12-31	Liabilities / assets	Not reported	Total Assets: 39727268 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 82323840 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 81941000 Open source
2018-12-31	Liabilities / assets	Not reported	Total Assets: 48803000 Open source
20192019-12-31	Liabilities / assets	62.5%	Total Liabilities: 1840000 Open source Total Assets: 2942000 Open source
20202020-12-31	Liabilities / assets	54%	Total Liabilities: 8100000 Open source Total Assets: 15013000 Open source
20212021-12-31	Liabilities / assets	25.9%	Total Liabilities: 7059000 Open source Total Assets: 27245000 Open source
20222022-12-31	Liabilities / assets	29.9%	Total Liabilities: 5697000 Open source Total Assets: 19073000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.9× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	9.66×	Current Assets: 38490140 Open source Current Liabilities: 3982698 Open source
20162016-12-31	Current assets / current liabilities	2.03×	Current Assets: 80452560 Open source Current Liabilities: 39559988 Open source
20172017-12-31	Current assets / current liabilities	2.82×	Current Assets: 79224000 Open source Current Liabilities: 28142000 Open source
20182018-12-31	Current assets / current liabilities	2.56×	Current Assets: 47426000 Open source Current Liabilities: 18521000 Open source
20192019-12-31	Current assets / current liabilities	1.78×	Current Assets: 2458000 Open source Current Liabilities: 1381000 Open source
20202020-12-31	Current assets / current liabilities	3.02×	Current Assets: 8400000 Open source Current Liabilities: 2785000 Open source
20212021-12-31	Current assets / current liabilities	9.27×	Current Assets: 21609000 Open source Current Liabilities: 2330000 Open source
20222022-12-31	Current assets / current liabilities	10.9×	Current Assets: 13456000 Open source Current Liabilities: 1234000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	−USD 15.62 million Exact value Exact value: -15616492 USD 2013-01-01 – 2013-12-31: -15616492 USD Inspect Net Income Open source Share or cite Citation for Net Income · Conatus Pharmaceuticals Inc · 2013-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Net Income: -15616492 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15616492 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459016014564/cnat-20151231.xml#102025 Filing: 000156459016014564 The citation records this snapshot. The page link may show a newer release later.	−USD 10.63 million Exact value Exact value: -10631717 USD 2013-01-01 – 2013-12-31: -10631717 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2013-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: -10631717 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10631717 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459016014564/cnat-20151231.xml#136126 Filing: 000156459016014564 The citation records this snapshot. The page link may show a newer release later.	USD 3,910 Exact value Exact value: 3910 USD 2013-01-01 – 2013-12-31: 3910 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2013-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 3910 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3910 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459016014564/cnat-20151231.xml#138159 Filing: 000156459016014564 The citation records this snapshot. The page link may show a newer release later.	−USD 10.64 million Calculation and evidence -10631717 − 3910 USD Exact free cash flow: -10635627 USD 2013-01-01 – 2013-12-31: -10631717 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 3910 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2013-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: -10635627 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10631717 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459016014564/cnat-20151231.xml#136126 Filing: 000156459016014564 Input fundies:CapitalExpenditure: 3910 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459016014564/cnat-20151231.xml#138159 Filing: 000156459016014564 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 22.32 million Exact value Exact value: -22319891 USD 2014-01-01 – 2014-12-31: -22319891 USD Inspect Net Income Open source Share or cite Citation for Net Income · Conatus Pharmaceuticals Inc · 2014-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Net Income: -22319891 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -22319891 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459017004617/cnat-20161231.xml#87785 Filing: 000156459017004617 The citation records this snapshot. The page link may show a newer release later.	−USD 18.26 million Exact value Exact value: -18260155 USD 2014-01-01 – 2014-12-31: -18260155 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2014-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: -18260155 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18260155 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459017004617/cnat-20161231.xml#114920 Filing: 000156459017004617 The citation records this snapshot. The page link may show a newer release later.	USD 242,681 Exact value Exact value: 242681 USD 2014-01-01 – 2014-12-31: 242681 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2014-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 242681 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 242681 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459017004617/cnat-20161231.xml#116954 Filing: 000156459017004617 The citation records this snapshot. The page link may show a newer release later.	−USD 18.5 million Calculation and evidence -18260155 − 242681 USD Exact free cash flow: -18502836 USD 2014-01-01 – 2014-12-31: -18260155 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 242681 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2014-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: -18502836 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18260155 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459017004617/cnat-20161231.xml#114920 Filing: 000156459017004617 Input fundies:CapitalExpenditure: 242681 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459017004617/cnat-20161231.xml#116954 Filing: 000156459017004617 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 24.15 million Exact value Exact value: -24148626 USD 2015-01-01 – 2015-12-31: -24148626 USD Inspect Net Income Open source Share or cite Citation for Net Income · Conatus Pharmaceuticals Inc · 2015-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Net Income: -24148626 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24148626 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459018004914/cnat-20171231.xml#111861 Filing: 000156459018004914 The citation records this snapshot. The page link may show a newer release later.	−USD 22.55 million Exact value Exact value: -22546185 USD 2015-01-01 – 2015-12-31: -22546185 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2015-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: -22546185 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22546185 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459018004914/cnat-20171231.xml#142787 Filing: 000156459018004914 The citation records this snapshot. The page link may show a newer release later.	USD 88,524 Exact value Exact value: 88524 USD 2015-01-01 – 2015-12-31: 88524 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2015-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 88524 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 88524 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459018004914/cnat-20171231.xml#144822 Filing: 000156459018004914 The citation records this snapshot. The page link may show a newer release later.	−USD 22.63 million Calculation and evidence -22546185 − 88524 USD Exact free cash flow: -22634709 USD 2015-01-01 – 2015-12-31: -22546185 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 88524 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2015-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: -22634709 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22546185 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459018004914/cnat-20171231.xml#142787 Filing: 000156459018004914 Input fundies:CapitalExpenditure: 88524 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459018004914/cnat-20171231.xml#144822 Filing: 000156459018004914 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 29.73 million Exact value Exact value: -29734000 USD 2016-01-01 – 2016-12-31: -29734000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Conatus Pharmaceuticals Inc · 2016-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Net Income: -29734000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29734000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459019007030/cnat-20181231.xml#106280 Filing: 000156459019007030 The citation records this snapshot. The page link may show a newer release later.	USD 27 million Exact value Exact value: 26997000 USD 2016-01-01 – 2016-12-31: 26997000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2016-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: 26997000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 26997000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459019007030/cnat-20181231.xml#153511 Filing: 000156459019007030 The citation records this snapshot. The page link may show a newer release later.	USD 110,000 Exact value Exact value: 110000 USD 2016-01-01 – 2016-12-31: 110000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2016-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 110000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 110000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459019007030/cnat-20181231.xml#155513 Filing: 000156459019007030 The citation records this snapshot. The page link may show a newer release later.	USD 26.89 million Calculation and evidence 26997000 − 110000 USD Exact free cash flow: 26887000 USD 2016-01-01 – 2016-12-31: 26997000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 110000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2016-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: 26887000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 26997000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459019007030/cnat-20181231.xml#153511 Filing: 000156459019007030 Input fundies:CapitalExpenditure: 110000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459019007030/cnat-20181231.xml#155513 Filing: 000156459019007030 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 17.4 million Exact value Exact value: -17396000 USD 2017-01-01 – 2017-12-31: -17396000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Conatus Pharmaceuticals Inc · 2017-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Net Income: -17396000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17396000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#130973 Filing: 000156459020010122 The citation records this snapshot. The page link may show a newer release later.	−USD 33.21 million Exact value Exact value: -33209000 USD 2017-01-01 – 2017-12-31: -33209000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2017-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: -33209000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33209000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#175519 Filing: 000156459020010122 The citation records this snapshot. The page link may show a newer release later.	USD 25,000 Exact value Exact value: 25000 USD 2017-01-01 – 2017-12-31: 25000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2017-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 25000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 25000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#177522 Filing: 000156459020010122 The citation records this snapshot. The page link may show a newer release later.	−USD 33.23 million Calculation and evidence -33209000 − 25000 USD Exact free cash flow: -33234000 USD 2017-01-01 – 2017-12-31: -33209000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 25000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2017-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: -33234000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33209000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#175519 Filing: 000156459020010122 Input fundies:CapitalExpenditure: 25000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#177522 Filing: 000156459020010122 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 18.01 million Exact value Exact value: -18010000 USD 2018-01-01 – 2018-12-31: -18010000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Conatus Pharmaceuticals Inc · 2018-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Net Income: -18010000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18010000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#130819 Filing: 000156459020010122 The citation records this snapshot. The page link may show a newer release later.	−USD 34.86 million Exact value Exact value: -34857000 USD 2018-01-01 – 2018-12-31: -34857000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2018-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: -34857000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34857000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#175307 Filing: 000156459020010122 The citation records this snapshot. The page link may show a newer release later.	USD 66,000 Exact value Exact value: 66000 USD 2018-01-01 – 2018-12-31: 66000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2018-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 66000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 66000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#177314 Filing: 000156459020010122 The citation records this snapshot. The page link may show a newer release later.	−USD 34.92 million Calculation and evidence -34857000 − 66000 USD Exact free cash flow: -34923000 USD 2018-01-01 – 2018-12-31: -34857000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 66000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2018-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: -34923000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34857000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#175307 Filing: 000156459020010122 Input fundies:CapitalExpenditure: 66000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#177314 Filing: 000156459020010122 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 11.39 million Exact value Exact value: -11385000 USD 2019-01-01 – 2019-12-31: -11385000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Conatus Pharmaceuticals Inc · 2019-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Net Income: -11385000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11385000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459020010122/cnat-20191231.xml#130665 Filing: 000156459020010122 The citation records this snapshot. The page link may show a newer release later.	−USD 1.29 million Exact value Exact value: -1291000 USD 2019-01-01 – 2019-12-31: -1291000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2019-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: -1291000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1291000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459021012536/hsto-20201231.xml#187573 Filing: 000156459021012536 The citation records this snapshot. The page link may show a newer release later.	USD 152,000 Exact value Exact value: 152000 USD 2019-01-01 – 2019-12-31: 152000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2019-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 152000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 152000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459021012536/hsto-20201231.xml#188347 Filing: 000156459021012536 The citation records this snapshot. The page link may show a newer release later.	−USD 1.44 million Calculation and evidence -1291000 − 152000 USD Exact free cash flow: -1443000 USD 2019-01-01 – 2019-12-31: -1291000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 152000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2019-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: -1443000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1291000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459021012536/hsto-20201231.xml#187573 Filing: 000156459021012536 Input fundies:CapitalExpenditure: 152000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459021012536/hsto-20201231.xml#188347 Filing: 000156459021012536 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	−USD 12.05 million Exact value Exact value: -12054000 USD 2020-01-01 – 2020-12-31: -12054000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2020-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: -12054000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12054000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459022009664/hsto-10k_20211231.htm#1836301 Filing: 000156459022009664 The citation records this snapshot. The page link may show a newer release later.	USD 49,000 Exact value Exact value: 49000 USD 2020-01-01 – 2020-12-31: 49000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2020-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 49000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 49000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459022009664/hsto-10k_20211231.htm#1851677 Filing: 000156459022009664 The citation records this snapshot. The page link may show a newer release later.	−USD 12.1 million Calculation and evidence -12054000 − 49000 USD Exact free cash flow: -12103000 USD 2020-01-01 – 2020-12-31: -12054000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 49000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2020-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: -12103000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12054000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459022009664/hsto-10k_20211231.htm#1836301 Filing: 000156459022009664 Input fundies:CapitalExpenditure: 49000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000156459022009664/hsto-10k_20211231.htm#1851677 Filing: 000156459022009664 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	−USD 14.53 million Exact value Exact value: -14532000 USD 2021-01-01 – 2021-12-31: -14532000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2021-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: -14532000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14532000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1936986 Filing: 000095017023007056 The citation records this snapshot. The page link may show a newer release later.	USD 241,000 Exact value Exact value: 241000 USD 2021-01-01 – 2021-12-31: 241000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2021-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 241000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 241000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1945110 Filing: 000095017023007056 The citation records this snapshot. The page link may show a newer release later.	−USD 14.77 million Calculation and evidence -14532000 − 241000 USD Exact free cash flow: -14773000 USD 2021-01-01 – 2021-12-31: -14532000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 241000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2021-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: -14773000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14532000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1936986 Filing: 000095017023007056 Input fundies:CapitalExpenditure: 241000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1945110 Filing: 000095017023007056 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	Unavailable Not reported for this period.	−USD 9.68 million Exact value Exact value: -9683000 USD 2022-01-01 – 2022-12-31: -9683000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Conatus Pharmaceuticals Inc · 2022-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Operating Cash Flow: -9683000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9683000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1934664 Filing: 000095017023007056 The citation records this snapshot. The page link may show a newer release later.	USD 216,000 Exact value Exact value: 216000 USD 2022-01-01 – 2022-12-31: 216000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Conatus Pharmaceuticals Inc · 2022-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Capital Expenditure: 216000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 216000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1942799 Filing: 000095017023007056 The citation records this snapshot. The page link may show a newer release later.	−USD 9.9 million Calculation and evidence -9683000 − 216000 USD Exact free cash flow: -9899000 USD 2022-01-01 – 2022-12-31: -9683000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 216000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Conatus Pharmaceuticals Inc · 2022-12-31 Conatus Pharmaceuticals Inc (edgar:1383701) Free cash flow: -9899000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:45:59Z Snapshot: 12730de2cf2198e8d055dc88f2ecadc91165505119bad207160b2560fcadc265 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1383701?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9683000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1934664 Filing: 000095017023007056 Input fundies:CapitalExpenditure: 216000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1383701/000095017023007056/hsto-20221231.htm#1942799 Filing: 000095017023007056 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

79 filings · 2,641 latest values · 2,636 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001383701, 1383701, CNAT, HSTO, edgar:1383701

Also known as CONATUS PHARMACEUTICALS INC., Conatus Pharmaceuticals Inc, Conatus Pharmaceuticals Inc., Histogen Inc.

Conatus Pharmaceuticals Inc

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation